

Research Article

Long-term results of celiac disease patients who underwent liver transplantation

Running title: Results of liver transplantation due to celiac

Caner Altun¹, Osman Saglam², Muhammed Furkan Keser³, Engin Ataman⁴, Cumali Savas Efe⁵, Hilal Burkek¹, Sezai Yilmaz⁶ Murat Harputluoglu⁷

¹Department of Internal Medicine, Inonu University Medical Faculty, Malatya, Turkiye

²Department of Gastroenterology, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkiye

³Department of Gastroenterology, School of Medical, Inonu University, Malatya, Turkiye

⁴Department of Gastroenterology, Necip Fazıl Ctiy Hospital, Kahramanmaraş, Turkiye

⁵Department of Gastroenterology, Harran University Medical Faculty, Sanliurfa, Turkiye

⁶Inonu University Medical Faculty, Liver Transplant Institute, General Surgery, Malatya, Turkiye

⁷School of Medical, Liver Transplant Institute, Transplant Hepatology, Inonu University Malatya, Turkiye

Caner Altun: <https://orcid.org/0000-0001-9512-8450>

Osman Saglam: <https://orcid.org/0000-0003-0779-992X>

Muhammed Furkan Keser: <https://orcid.org/0000-0002-4524-9761>

Engin Ataman: <https://orcid.org/0000-0001-9751-3571>

Cumali Savas Efe: <https://orcid.org/0000-0001-6593-5702>

Hilal Burkek: <https://orcid.org/0009-0001-1757-951X>

Sezai Yilmaz <https://orcid.org/0000-0002-8044-0297>

Murat Harputluoglu: <https://orcid.org/0000-0002-9415-147X>

How to cite this article: Altun C, Saglam O, Keser MF, Ataman E, Efe CS, Burkek H, et al. Long-term results of celiac disease patients who underwent liver transplantation. Hepatology Forum 2025; 6(4):XXX–XXX.

Received: March 06, 2025; **Revised:** May 31, 2025; **Accepted:** August 05, 2025;

Corresponding author:

Muhammed Furkan KESER, Department of Gastroenterology, School of Medical, Inonu University, Malatya, Türkiye

Phone: +90 534 547 96 86; **e-mail:** furkankeser@gmail.com

Ethics Committee Approval: This study was carried out with the permission of the Inonu University Ethics Committee with the decision number 2024/5649.

Conflict of Interest: There are no conflicts of interest in connection with this paper, and the material described is not under publication or consideration for publication elsewhere.

Financial Disclosure: The authors declared that this study has received no financial support.

Use of AI for Writing Assistance: The study did not use AI-enabled technology.

Author Contributions: Concept – CA, OS, MFK, EA, CSE, HB, SY, MH; Design – CA, OS, MFK, EA, CSE, HB, SY, MH; Supervision – CA, OS, MFK, EA, CSE, HB, SY, MH; Fundings – CA, SY, HB; Materials – MH, EA, OS; Data Collection and/or Processing – CA, SY, HB; Analysis and/or Interpretation – MFK, EA, OS; Literature Search – MH, SY, OS; Writing – CA, MH, MFK; Critical Review – MH, CSE.

Peer-review: Externally peer-reviewed.

Abstract

Background and aim: Although there are a few studies reporting transplantation for celiac disease (CD), there are no studies reporting long-term outcomes after transplantation in CD patients. Therefore, we aimed to report the long-term outcomes of patients who underwent liver transplantation (LT) for CD in our high-volume liver transplantation center.

Materials and Methods: Our study was a single-center, retrospective study and included 28 CD patients who underwent LT at Inonu University. CD diagnosis was made based on anti-tissue transglutaminase or anti-endomysium antibody positivity and/or duodenal biopsy results.

Results: The 1-, 3-, 5-, and 10-year survival rates after transplantation were 92.9%, 92.9%, 84.4%, and 75%, respectively. The most striking finding in the study was the high frequency

of biliary complications. Another important finding was the significant difference in body mass index (BMI) between pre-transplant and post-transplant ($p<0.001$). The incidence of rejection and recurrence was 39.1% and 25%, respectively. The number of patients with high anti-tissue transglutaminase (anti-TTG) levels after transplantation decreased significantly ($p<0.001$).

Conclusion: Our study suggests that the frequency of post-transplant biliary complications is very high in CD patients and that LT had positive effects on BMI and anti-tissue transglutaminase levels.

Key words: Celiac disease; liver; transplantation.

Introduction

Celiac disease (CD) is a T-cell autoimmune disorder of the small intestine characterized by malabsorption resulting from the ingestion of gluten, the main protein fraction in wheat, rye, and barley, in genetically predisposed individuals. The prevalence in the general population varies between 0.5% and 2%, with an average of around 1%. [1] Although CD is defined as a disease with malabsorption in the small intestine, untreated cases also affect other organs, including the liver. Liver involvement may progress to end-stage liver failure in patients who do not adhere to a gluten-free diet. [2] There is also a close relationship between celiac disease and autoimmune liver disease. Studies have found the prevalence of celiac disease to be 3–7% in patients with primary biliary cirrhosis, 3–6% in patients with autoimmune hepatitis, and 2–3% in patients with primary sclerosing cholangitis. [3–5]

In liver transplant patients with end-stage liver disease from different causes, the prevalence of CD varies between 3% and 4.3%. [2] Although there are a few studies reporting transplantation for CD, [6] there are no studies reporting long-term outcomes after transplantation in CD patients. Therefore, we aimed to report the long-term outcomes of CD patients who underwent liver transplantation in our high-volume liver transplantation center.

Materials and Methods

Our study was a single-center, retrospective study and included 28 CD patients who underwent liver transplantation at Inonu University between January 2004 and December 2023. Celiac disease diagnosis was made based on anti-tissue transglutaminase or anti-endomysium antibody positivity and/or duodenal biopsy results. Among patients who underwent transplantation due to cryptogenic cirrhosis, patients with positive anti-tissue transglutaminase or anti-endomysium antibody were also considered as celiac patients. Clinical and laboratory data of patients were obtained by reviewing the patients' electronic files. This study was carried out with the permission of the Inonu University Ethics Committee with the decision number 2024/5649. The study was conducted in accordance with the Declaration of Helsinki.

Pre-transplant parameters:

Patients' age, gender, blood group, concomitant diseases, transplantation type (living donor-cadaveric), Model End Stage Liver Disease-Na (MELD-Na) scores at the time of transplantation, anti-tissue transglutaminase level before and after transplantation, presence of iron deficiency anemia and osteoporosis, body mass index, transplantation indication, donor's age, gender, blood group, consanguinity between the donor and the recipient,

presence of Rh-incompatible transplantation, and presence of hepatocellular carcinoma were recorded.

Post-transplant parameters:

Presence of hepatocellular carcinoma after transplantation, immunosuppressive treatment used after transplantation, use of ursodeoxycholic acid or steroids after transplantation, survival time, causes of death, presence of diarrhea after transplantation, presence of portal vein thrombosis, hepatic vein thrombosis, hepatic artery thrombosis after transplantation (if any), duration, development of recurrence and rejection, relationship with other malignancies, presence of second and third transplantation, cytomegalovirus infection, biliary complication frequency and feature, type of bile duct anastomosis (duct-to-duct anastomosis/hepaticojejunal anastomosis), treatment of post-transplant biliary complications, and liver biopsy results (acute rejection, chronic rejection, antibody-mediated rejection, disease recurrence, if any) were recorded.

Statistical analyses

The analyses were evaluated using SPSS (Statistical Package for Social Sciences; SPSS Inc., Chicago, IL) version 22. In the study, descriptive data were shown as n, % values for categorical data and as mean \pm standard deviation (Mean \pm SD) values for continuous data. Chi-square analysis (Pearson Chi-square) was applied to compare categorical variables between groups. The Kolmogorov-Smirnov test was used to evaluate the compliance of continuous variables with normal distribution. Student t-test was used to compare binary groups. In the analyses, the statistical significance level was accepted as $p < 0.05$.

Results

A total of 28 patients were included in the study: 12 (42.9%) male and 16 (57.1%) female. The mean age of the patients was 21.3 ± 14.1 years. Eight patients were younger than 18 years old. Two (7.1%) of the transplants were deceased donor, and 26 (92.9%) were living donor liver transplantation. The mean follow-up period of the patients was 73.3 ± 46.1 months. Table 1 shows demographic characteristics of patients undergoing liver transplantation due to CD.

The results of all patients after liver transplantation are summarized in Table 2. One of the six patients who died had a deceased donor transplant. Half of the deaths were biliary and the other half were secondary to rejection. The 12-month and 36-month survival rates were 92.9%; the 60-month survival rate was 84.4%, and the 120-month survival rate was 75% (Fig. 1). Factors affecting mortality were analyzed, and only age was found to be a significant factor. The average age of those who died was significantly lower than the average age of those who did not die ($p = 0.041$). Other parameters had no significant effect on mortality ($p > 0.05$) (Table 3).

The most striking finding in the study was the high frequency of biliary complications. Biliary complications were found to develop in one of two deceased donor transplants (50%) and in 73% of living donor transplants. Biliary complications occurred in 3 of 4 patients (75%) with HJ and 17 of 24 patients (70.8%) with duct-to-duct anastomosis. Of the patients with duct-to-duct anastomosis, 11 had biliary stricture, 3 had stricture and leakage, and 3 had stricture and stones. Of the patients with HJ, 2 had stricture and 1 had leakage. All patients with HJ and biliary complications (100%) were successfully treated with percutaneous transhepatic biliary interventions (PTBI). ERCP was performed in 16 patients with duct-to-duct anastomosis and biliary complications, and biliary problems were resolved in 9 patients with ERCP. The endoscopic success rate was 56.2%. PTBI was performed in 7 patients with

duct-to-duct anastomosis. One patient with duct-to-duct anastomosis and biliary complications recovered with medical treatment without the need for any interventional treatment. All patients with duct-to-duct anastomosis and biliary complications (100%) were successfully treated with ERCP + PTBI. Surgery was not performed in any patient with biliary complications.

Another important finding was the significant difference in BMI between pre-transplant and post-transplant ($p < 0.001$, Fig. 2). While 39.3% of the patients had a BMI of < 18 before transplantation, 46.4% had a BMI of 18–25 and 14.3% had a BMI of 25–30. After transplantation, 21.4% of the patients had a BMI of < 18 , 71.4% had a BMI of 18–25, and 7.1% had a BMI of 25–30.

Celiac recurrence developed in 7 patients, and these patients had living donor transplants except for one patient. Six of these patients had no dietary compliance after transplantation. Among the patients who underwent living donor transplantation, 2 developed acute rejection, 4 developed chronic rejection, and 3 developed antibody-mediated rejection. It was found that half of deceased transplant patients (1/2, 50%) developed chronic rejection. A total of 11 patients (39.3%) developed rejection.

While 77.8% of the patients had high anti-tissue transglutaminase levels before transplantation, this rate became 10.5% after transplantation, and the rate of normality increased significantly ($p < 0.001$). Iron deficiency anemia, osteoporosis, and duodenal biopsy results of the patients before and after transplantation did not change significantly ($p > 0.05$). The frequency of iron deficiency anemia was 35.7% (10/28) before transplantation and 46.4% (13/28) after transplantation. The frequency of osteoporosis was 10.7% (3/28) before transplantation and 17.9% (5/28) after transplantation. Findings compatible with celiac disease in duodenal biopsy were 32.1% (9/28) before transplantation and 25% (7/28) after transplantation.

Discussion

In our study, we found the 1-, 3-, 5-, and 10-year survival rates in CD patients who underwent transplantation to be 92.9%, 92.9%, 84.4%, and 75%, respectively. The mean age of patients who died after transplantation was significantly lower than that of survivors. We also found that liver transplantation had positive effects on BMI and anti-tissue transglutaminase levels. One of the most striking findings in our study was the high frequency of biliary complications.

Since there are very few publications in the literature on liver transplantation outcomes due to CD, we had to compare our results, especially regarding survival, with the results after liver transplantation due to autoimmune diseases. In a study conducted by Mottershead et al. in 2008 on patients who underwent liver transplantation due to autoimmune hepatitis, 1- and 5-year survival rates were found to be 87% and 80–90%, respectively.[7] In two different studies, post-transplant survival rates in patients with autoimmune hepatitis were also reported as 85–97% and 78.4%, respectively.[8, 9] In the European Liver Transplant Registry, the 5- and 10-year survival rates for PSC were 80% and 83% after transplantation.[10] In a study conducted by Egawa et al. on 444 patients who underwent transplantation due to PBC, 5-year survival was found to be 76.6%.[11] The survival rate of CD patients who underwent liver transplantation in our center is similar to liver

transplantations performed due to other autoimmune diseases worldwide. Our results suggest that survival rates after liver transplantation are quite satisfactory in patients with end-stage liver disease due to CD, for which no other treatment options are available.

In our study, recurrence was observed in 7 (28%) patients who underwent liver transplantation due to CD. In a study conducted by Alabraba et al., recurrence was observed in 259 (18.5%) of 1,399 patients who underwent liver transplantation due to PSC.[12] In two studies, the recurrence rate after liver transplantation in patients with AIH was 17.9% and 41%, respectively.[9,13] Khettry et al. reported that 18.6% of 43 PBC-related transplant patients developed recurrence.[14] Our results suggest that the recurrence rate after liver transplantation due to CD is similar to other autoimmune diseases.

Since CD is an autoimmune disease, it may be accompanied by other autoimmune diseases. The prevalence of autoimmune hepatitis in celiac disease is 1.6%.[15] Lawson et al. reported the prevalence of PBC as 0.1% in a study of 4,732 CD patients.[16] In a study including a very large number (136,735) of CD patients, the prevalences of AIH, PBC, and PSC were 0.32%, 0.15%, and 0.004%, respectively.[17] Kaukinen et al. reported that CD was detected in 8 of 185 liver transplant patients. Among the patients with CD, 3 had primary biliary cirrhosis, 1 had autoimmune hepatitis, 1 had primary sclerosing cholangitis, 1 had congenital liver fibrosis, and 1 had secondary sclerosing cholangitis.[18]

In our study, in patients who underwent transplantation due to CD, 46% had autoimmune hepatitis, 3.5% had PBC, 3.5% had IgA nephropathy, and 3.5% had Type 1 DM. All these data and our results suggest that the frequency of AIH and PBC is higher in CD patients with liver transplantation and that autoimmune liver diseases may coexist in CD patients with liver transplantation.

In our study, it was observed that the number of patients with high anti-TTG levels after transplantation decreased significantly. In a study conducted by Rubio-Tapia et al.[2] on patients who underwent liver transplantation due to CD, it was reported that the rate of patients with pre-transplant anti-TTG positivity decreased significantly after transplantation and even became negative. One study suggested that there may be two reasons for the decrease in anti-TTG levels after transplantation in CD patients. The first reason is that removal of the diseased liver reduces the level of anti-TTG antibodies, as it may be a target organ. The second reason is that immunosuppressive drugs used after transplantation affect the production of autoantibodies.[19] In addition, correction of intestinal barrier dysfunction caused by cirrhosis after transplantation may also reduce the antigenic environment and B-cell activation and lead to normalization of anti-TTG.[2] Our results are similar to the study by Rubio-Tapia et al.[2], suggesting that liver transplantation has a positive effect on anti-TTG levels in CD patients who underwent liver transplantation.

In our study, post-transplant acute and chronic rejection rates in CD patients were 7% and 21.4%, respectively. In the study conducted by Rubio-Tapia et al.[2], it was reported that 3 (30%) of 10 double (anti-TTG and EMA) positive patients developed rejection. In a study conducted by Yasmina et al. on a large number of patients who underwent liver transplantation due to autoimmune hepatitis, acute rejection was detected in an average of 23.5%, and this rate decreased from 45.7% in the early years of liver transplantation to 13.4% over the years.[20] The AASLD AIH guideline reported the incidence of chronic rejection as 16% for AIH, 5.2% for PSC, and 8.2% for PBC.[21] In a study conducted by our group at our center on patients who underwent liver transplantation due to PSC, the incidence of acute and

chronic rejection was 13.3% and 10%, respectively.[22] Our results suggest that the rate of post-transplant rejection in patients with CD in our center is higher than liver transplants performed for other autoimmune diseases worldwide. In addition, although the number of studies reporting the frequency of post-transplant rejection in CD patients is very small, the results of Rubio-Tapia et al.[2] and ours suggest that post-transplant rejection is common in CD patients.

In our study, the frequency of post-transplant biliary complications was found to be quite high. Biliary complications occurred in 50% of deceased donor liver transplants and 73% of living donor liver transplants. There are studies reporting the frequency of biliary complications after transplantation in AIH and PSC patients as 25.3% and 36.1%, respectively. [20, 23] In a study including a large number of patients, biliary complications were reported in 11.1% of 6,471 deceased donor liver transplant patients and in 20.8% of 389 living donor liver transplant patients.[24] It has been reported that ERCP was applied to 283 (18.7%) of 1,506 LDLT patients with duct-to-duct anastomosis in our institute between 2015 and 2021.[25] The majority of the patients in our study had living donor LT. Therefore, it is possible that our results are related to technical reasons associated with living donors. However, because of the small number of patients in our study, it is not easy to interpret whether the high frequency of biliary complications is related to celiac disease or technical reasons. Although our case number is small, our results suggest that the frequency of post-transplant biliary complications in CD is higher than in other autoimmune diseases.

Another important finding in our study was the significant difference in BMI before and after transplantation. Our results suggest that liver transplantation provides significant benefits on weight gain in CD. In this study, no significant change was detected in the iron deficiency anemia (IDA), osteoporosis, and duodenal biopsy results of the patients before and after transplantation. The lack of change in the frequency of osteoporosis may be related to the side effects of immunosuppressive drugs used after transplantation on the bones. Our result regarding iron deficiency anemia can also be explained by the lack of positive change in small intestine histology after transplantation.

Conclusion

Our results suggest that the frequency of post-transplant biliary complications is very high in CD patients and that LT had positive effects on BMI and anti-tissue transglutaminase levels.

References

1. Catassi C, Verdu EF, Bai JC, Lionetti E. Coeliac disease. *Lancet* 2022;399(10344):2413-2426. [\[CrossRef\]](#)
2. Rubio-Tapia A, Abdulkarim AS, Wiesner RH, Moore SB, Krause PK, Murray JA. Celiac disease autoantibodies in severe autoimmune liver disease and the effect of liver transplantation. *Liver Int* 2008;28(4):467-476. [\[CrossRef\]](#)
3. Nastasio S, Sciveres M, Riva S, Filippeschi IP, Vajro P, Maggiore G. Celiac Disease—Associated Autoimmune Hepatitis in Childhood. *J Pediatr Gastroenterol Nutr* 2013;56(6):671-674. [\[CrossRef\]](#)

4. Caprai S, Vajro P, Ventura A, Sciveres M, Maggiore G. Autoimmune liver disease associated with celiac disease in childhood: a multicenter study. *Clin Gastroenterol Hepatol* 2008;6(7):803-806. [\[CrossRef\]](#)
5. Volta U, Rodrigo L, Granito A, Petrolini N, Muratori P, Muratori L, et al. Celiac disease in autoimmune cholestatic liver disorders. *Am J Gastroenterol* 2002;97(10):2609-2613. [\[CrossRef\]](#)
6. Pavone P, Gruttadauria S, Leonardi S, Sorge G, Minervini MI, Greco F, et al. Liver transplantation in a child with celiac disease. *J Gastroenterol Hepatol* 2005;20(6):956-960. [\[CrossRef\]](#)
7. Mottershead M, Neuberger J. Transplantation in autoimmune liver diseases. *World J Gastroenterol* 2008;14(21):3388-3395. [\[CrossRef\]](#)
8. Ratziu V, Samuel D, Sebah M, Farges O, Saliba F, Ichai P, et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: Evidence of recurrence of primary disease. *J Hepatol* 1999;30(1):131-141. [\[CrossRef\]](#)
9. Vogel A, Heinrich E, Bahr MJ, Rifai K, Flemming P, Melter M, Klempnauer J, Nashan B, Manns MP, Strassburg CP. Long-term outcome of liver transplantation for autoimmune hepatitis. *Clin Transplant* 2004;18(1):62-69. [\[CrossRef\]](#)
10. Visseren T, Erler NS, Polak WG, Adam R, Karam V, Vondran FWR, et al; European Liver and Intestine Transplantation Association (ELITA). Recurrence of primary sclerosing cholangitis after liver transplantation-analysing the European Liver Transplant Registry and beyond. *Transpl Int* 2021;34(8):1455-1467. [\[CrossRef\]](#)
11. Egawa H, Sakisaka S, Teramukai S, Sakabayashi S, Yamamoto M, Umeshita K, et al. Long-term outcomes of living-donor liver transplantation for primary biliary cirrhosis: a Japanese multicenter study. *Am J Transplant* 2016;16(4):1248-1257. [\[CrossRef\]](#)
12. Alabraba E, Nightingale P, Gunson B, Hubscher S, Olliff S, Mirza D, Neuberger J. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. *Liver Transpl* 2009;15(3):330-340. [\[CrossRef\]](#)
13. Duclos-Vallée JC, Sebah M, Rifai K, Johanet C, Ballot E, Guettier C, et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. *Gut* 2003;52(6):893. [\[CrossRef\]](#)
14. Khettry U, Anand N, Faul PN, Lewis WD, Pomfret EA, Pomposelli J, et al. Liver transplantation for primary biliary cirrhosis: A long-term pathologic study. *Liver Transpl* 2003;9(1):87-96. [\[CrossRef\]](#)

15. Novacek G, Miehsler W, Wrba F, Ferenci P, Penner E, Vogelsang H. Prevalence and clinical importance of hypertransaminasaemia in coeliac disease. *Eur J Gastroenterol Hepatol* 2009;11(3):283-288. [\[CrossRef\]](#)
16. Lawson A, West J, Aithal GP, Logan RFA. Autoimmune cholestatic liver disease in people with coeliac disease: a population-based study of their association. *Aliment Pharmacol Ther* 2005;21(4):401-405. [\[CrossRef\]](#)
17. Hitawala AA, Almomani A, Onwuzo S, Boustany A, Kumar P, Asaad I. Prevalence of autoimmune, cholestatic and nonalcoholic fatty liver disease in celiac disease. *Eur J Gastroenterol Hepatol* 2023;35(9):1030-1036. [\[CrossRef\]](#)
18. Kaukinen K, Halme L, Collin P, Färkkilä M, Mäki M, Vehmanen P, et al. Celiac disease in patients with severe liver disease: Gluten-free diet may reverse hepatic failure. *Gastroenterology* 2002;122(4):881-888. [\[CrossRef\]](#)
19. Ecevit Ç, Karakoyun M, Ünal F, Yüksekaya HA, Doğanavşargil B, Yağcı RV, et al. An autoimmune disease refractory to immunosuppressive regimens: celiac disease diagnosed long after liver transplantation. *Pediatr Transplant* 2013;17(7):E156-E160. [\[CrossRef\]](#)
20. Chouik Y, Francoz C, De Martin E, Guillaud O, Abergel A, Altieri M, et al. Liver transplantation for autoimmune hepatitis: Pre-transplant does not predict the early post-transplant outcome. *Liver Int* 2023;43(4):906-916. [\[CrossRef\]](#)
21. Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. *Hepatology* 2020;72(2):671-722. [\[CrossRef\]](#)
22. Harputluoglu MMM, Calgin MZ, Ataman E, Kutluturk K, Kutlu R, Yılmaz S. Outcomes of patients with primary sclerosing cholangitis after liver transplantation in a predominantly living donor liver transplant center. *J Liver Transpl* 2023;12:100186. [\[CrossRef\]](#)
23. Hildebrand T, Pannicke N, Dechene A, Gotthardt DN, Kirchner G, Reiter FP, et al; German PSC Study Group. Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A retrospective multicenter analysis. *Liver Transpl* 2016;22(1):42-52. [\[CrossRef\]](#)
24. Hu Z, Qian Z, Wu J, Zhou J, Zhang M, Zhou L, Zheng S. Clinical outcomes and risk factors of hepatocellular carcinoma treated by liver transplantation: A multi-centre comparison of living donor and deceased donor transplantation. *Clin Res Hepatol*

Gastroenterol. 2016;40:315–326. [\[CrossRef\]](#)

25. Ataman E, Harputluoglu M, Bilgic Y, Cagin YF, Erdogan MA, Kutlu R, et al. The course of endoscopic treatment success in biliary complications after living donor liver transplantation. Medeni Med J 2024;39(1):33-38. [\[CrossRef\]](#)

Ahead of print

Table 1. Demographic characteristics of patients undergoing liver transplantation due to Celiac disease.

MELD: The Model for End-Stage Liver Disease, HCC: Hepatocellular carcinoma, HJ: hepaticojejunostomy.

		Cadaveric (n=2)		Living donor (n=26)		Total (n=28)	
		Nu mbe r	%	Num ber	%	Nu mbe r	%
Gender	Male	0	0	12	46.2	12	42.9
	Female	2	100	14	53.8	16	57.1
Age, Mean±SD (Median)		18.0±17.0 (18.0)		21.6±14.2 (19.50)		21.3±14.1 (19.50)	
Follow-up period, Mean±SD (months)		58.5±26.2		74.4±47.5		73.3±46.1	
Dietary compliance before transplantation	Yes	1	50	4	15.4	5	17.9
	No	1	50	22	84.6	23	82.1
HCC before transplantation	Yes	1	50	2	7.7	3	10.7
	No	1	50	24	92.3	25	89.3
Associated disease	Yes	0	0	18	69.2	18	64.3
	No	2	100	8	30.8	10	35.7
Associated disease	Type 1 Diabetes Mellitus	0	0	1	5.6	1	5.6
	Primary biliary cholangitis+Crohn	0	0	1	5.6	1	5.6
	Irritable bowel syndrome	0	0	1	5.6	1	5.6
	IgA Nephropathy	0	0	1	5.6	1	5.6
	Autoimmune hepatitis	0	0	13	72.2	13	72.2
	Fibrocystic liver disease	0	0	1	5.6	1	5.6
Transplant indication	High MELD score	1	50	19	73.1	20	71.4
	Persistent pruritus	0	0	1	3.8	1	3.6
	Portal Hypertension-related complications	0	0	6	23.1	6	21.4
	HCC	1	50	0	0	1	3.6
	HJ	1	50	3	11.6	4	14.3
Bile duct anastomosis	Duct-to duct	1	50	23	88.4	24	85.7

Ahead of print

Table 2. The results of all patients after liver transplantation

		Cadaveric (n=2)	Living donor (n=26)	Total (n=28)
Drugs after transplantation	Tacrolimus	0 (0%)	2 (7.7%)	2 (7.1%)
	Everolimus+Tacrolimus+MMF	1 (50%)	8 (30.8%)	9 (32.1%)
	Tacrolimus + MMF	1 (50%)	7 (26.9%)	8(28.6%)
	Tacrolimus+ Cyclosporine +Everilumus+MMF	0 (0%)	7 (26.9%)	7 (25.0%)
	Unknown	0 (0%)	1 (3.8%)	1 (3.6%)
	Tacrolimus+Everilumus+ Cyclosporine	0 (0%)	1 (3.8%)	1 (3.6%)
	Corticosteroid	0 (0%)	4 (15.4%)	4 (14.3%)
	UDCA	1 (50%)	3 (11.5%)	4 (14.3%)
	Corticosteroid + UDCA	1 (50%)	18 (69.2%)	19(67.9%)
Death	Yes	1 (50%)	5 (19.2%)	6 (21.4%)
	No	1 (50%)	21 (80.8%)	22 (78.6%)
Cause of death	Biliary sepsis	1 (50%)	2 (7.6%)	3 (10.7%)
	Rejection	0 (0%)	3 (11.5%)	3 (10.7%)
Recurrence	Yes	1 (50%)	6 (23.1%)	7 (25%)
	No	1 (50%)	20 (76.9%)	21 (75%)
Rejection	Var	1 (50%)	10 (38.5%)	11 (39.3%)
	Yok	1 (50%)	16 (61.5%)	17 (60.7%)
Biliary complication	Yes	1 (50%)	19 (73%)	20 (71.4%)
	No	1 (50%)	7 (27%)	8 (28.6%)
Second transplantation	Yes	0 (0%)	3 (11.5%)	3 (10.7%)
	No	2 (100%)	23 (88.5%)	25 (89.3%)
Portal vein thrombosis	Yes	0 (0%)	2 (7.7%)	2 (7.1%)
	No	2(100%)	24 (92.3%)	26(92.9%)
Hepatic arthery thrombosis	Yes	0 (0%)	1 (3.8%)	1 (3.6%)
	No	2(100%)	25 (96.2%)	27 (96.4%)
Hepatic vein thrombosis	Yes	0 (0%)	1 (3.8%)	1 (3.6%)
	No	2(100%)	25 (96.2%)	27 (96.4%)
Surgery for biliary complication	Yes	0 (0%)	0 (0%)	0 (0%)
	No	2(100%)	26 (100%)	28 (100%)
ERCP	Yes	1 (50%)	15 (57.7%)	16 (57.1%)
	No	1 (50%)	11 (42.3%)	12 (42.9%)
PTBI	Yes	1 (50%)	9 (34.6%)	10 (35.7%)
	No	1 (50%)	17 (65.3%)	18 (64.3%)
CMV	Yes	1 (50%)	2 (7.7%)	3 (10.7%)
	No	1 (50%)	24 (92.3%)	25 (89.3%)

HCC after	Yes	0 (0%)	0 (0%)	0 (0%)
transplantation	No	2 (100%)	26 (100%)	28 (100%)
Diarrhea after	Yes	1 (50%)	6 (23.1%)	7 (25.0%)
transplantation	No	1 (50%)	20 (76.9%)	21(75.0%)

MMF: Mycophenolate mofetil; UDCA: Ursodeoxycholic acid; ERCP: Endoscopic cholangiopancretaography;
PTBI: Percutaneous transhepatic biliary intervention; CMV: Cytomegalovirus; HCC: Hepatocellular carcinoma.

Ahead of print

Ahead of print

Table 3. Factors affecting mortality

		Death				p [*]
		Yes		No		
		Number	%	Number	%	
Gender	Male	2	16.7	10	83.3	0.673
	Female	4	25	12	75.0	
Biliary complication	Yes	5	21.1	15	78.9	0.871
	No	1	22	7	78	
Type of biliary complications	Stricture	3	23	10	76.9	0.247
	Leak	1	100	0	0	
	Stricture + leak	0	0	3	100	
	Stricture + stone	1	33	2	66	
MELD before LT	0-15	1	12.5	7	87.5	0.640
	>15	5	25.0	15	75.0	
Blood group	A	3	30.0	7	70.0	0.880
	B	1	12.5	7	87.5	
	0	2	22.2	7	77.8	
	AB	0	0	1	100	
BMI before LT	<18	3	27.3	8	72.7	0.696
	18-25	3	23.1	10	76.9	
	25-30	0	0	4	100	
BMI after LT	<18	3	50.0	3	50	0.130
	18-25	3	15.0	17	85.0	
	25-30	0	0	2	100.0	
Dietary compliance before LT	Yes	1	20.0	4	80.0	0.932
	No	5	21.7	18	78.3	
Dietary compliance after LT	Yes	0	0	4	100	0.549
	No	6	25.0	18	75.0	
Donor Gender	Male	3	27.3	8	72.7	0.653
	Female	3	17.6	14	82.4	
Age, Mean±SD		29.5±10.5		41.2±16.1		0.041
Donor Blood Group	A	2	20.0	8	80.0	0.826
	B	0	0	4	100.0	
	0	4	28.6	10	71.4	
Donor degree of kinship (1st degree)	Yes	2	10.5	17	89.5	0.064
	No	4	44.4	5	55.6	
Rh incompatibility	Yes	0	0	2	100.0	0.443
	No	6	23.1	20	76.9	
HCC before LT	Yes	2	66.7	1	33.3	0.107
	No	4	16.0	21	84.0	
HCC after LT	Yes	0	0	0	0	-
	No	6	21.4	22	78.6	
Associated Disease	Yes	4	22.2	14	77.8	0.891

	No	2	20.0	8	80.0	
PVT after LT	Yes	0	0	2	100.0	0.443
	No	6	23.1	20	76.9	
HAT after LT	Yes	1	100.0	0	0	0.214
	No	5	18.5	22	81.5	
HVT after LT	Yes	0	0	1	100.0	0.595
	No	6	22.2	21	77.8	
CMV	Yes	0	0	3	100.0	0.338
	No	6	24.0	19	76.0	

MELD: The model for end-stage liver disease; BMI: Body mass index; HCC: Hepatocellular carcinoma; PVT: Portal vein thrombosis; HAT: Hepatic artery thrombosis; HVT: Hepatic vein thrombosis; CMV: Cytomegalovirus; LT: Liver transplantation.




Figure 1. Kaplan–Meier survival curve of celiac disease patients after liver transplantation






Figure 2. Comparison of body mass index (BMI) before and after liver transplantation in celiac disease patients



Ahead



Ahead